| Drug General Information |
| Drug ID |
D0W7RI
|
| Former ID |
DIB019061
|
| Drug Name |
carbacyclin
|
| Synonyms |
carboprostacyclin
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
|
| Formula |
C21H34O4
|
| InChI |
InChI=1S/C21H34O4/c1-2-3-4-8-17(22)10-11-18-19-13-15(7-5-6-9-21(24)25)12-16(19)14-20(18)23/h7,10-11,16-20,22-23H,2-6,8-9,12-14H2,1H3,(H,24,25)/b11-10+,15-7-/t16-,17-,18+,19-,20+/m0/s1
|
| InChIKey |
XZFRIPGNUQRGPI-WLPVIMDJSA-N
|
| PubChem Compound ID |
|
| PubChem Substance ID |
7979794, 11056373, 39340950, 76891886, 103388580, 104004496, 114155649, 135650056, 235992185, 241122451, 250133448, 252457378, 252467026
|
| Target and Pathway |
| Target(s) |
Thromboxane A2 receptor |
Target Info |
Agonist |
[2]
|
|---|
| Prostaglandin E2 receptor, EP4 subtype |
Target Info |
Agonist |
[3]
|
| Prostaglandin D2 receptor |
Target Info |
Agonist |
[2]
|
| Prostaglandin E2 receptor, EP1 subtype |
Target Info |
Agonist |
[2]
|
| Prostacyclin receptor |
Target Info |
Agonist |
[2]
|
| Prostaglandin F2-alpha receptor |
Target Info |
Agonist |
[2]
|
| Prostaglandin E2receptor, EP2 subtype |
Target Info |
Agonist |
[2]
|
| Prostaglandin E2 receptor EP3 subtype |
Target Info |
Agonist |
[3]
|
|
KEGG Pathway
|
Calcium signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Platelet activationhsa04080:Neuroactive ligand-receptor interaction
|
|
Inflammatory mediator regulation of TRP channels
|
|
Renin secretion
|
|
Pathways in cancerhsa04080:Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway
|
|
Pathways in cancerhsa04080:Neuroactive ligand-receptor interaction
|
|
Vascular smooth muscle contraction
|
|
Platelet activationhsa04020:Calcium signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway
|
|
Pathways in cancerhsa04020:Calcium signaling pathway
|
|
cAMP signaling pathway
|
|
Regulation of lipolysis in adipocytes
|
|
Pathways in cancer
|
|
NetPath Pathway
|
FSH Signaling Pathway
|
|
IL2 Signaling Pathway
|
|
IL4 Signaling Pathway
|
|
TGF_beta_Receptor Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
PI3 kinase pathway
|
|
Pathway Interaction Database
|
Thromboxane A2 receptor signalingtxa2pathway:Thromboxane A2 receptor signaling
|
|
PathWhiz Pathway
|
Intracellular Signalling Through PGD2 receptor and Prostaglandin D2PW000452:Intracellular Signalling Through Prostacyclin Receptor and Prostacyclin
|
|
Reactome
|
Prostanoid ligand receptors
|
|
G alpha (q) signalling events
|
|
G alpha (12/13) signalling events
|
|
Thromboxane signalling through TP receptorR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (s) signalling eventsR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (q) signalling eventsR-HSA-391908:Prostanoid ligand receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
GPCRs, Class A Rhodopsin-like
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
Small Ligand GPCRs
|
|
Signal amplification
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation
|
|
Vitamin D Receptor Pathway
|
|
Endothelin Pathways
|
|
Platelet homeostasis
|
|
GPCR downstream signaling
|
|
GPCRs, OtherWP98:Prostaglandin Synthesis and Regulation
|
|
Ovarian Infertility Genes
|
| References |
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1893). |
|---|
| REF 2 | The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. |
|---|
| REF 3 | Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. |
|---|
